CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02798406
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:06.569954+00:00
Published At: 2021-07-15T00:00:00+00:00
Record Updated At: 2021-07-15
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Brain Cancer", "Brain Neoplasm", "Glioma", "Glioblastoma", "Gliosarcoma", "Malignant Brain Tumor", "Neoplasm, Neuroepithelial", "Neuroectodermal Tumors", "Neoplasm by Histologic Type", "Neoplasm, Nerve Tissue", "Nervous System Diseases"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2021-07-15"
protocolSection.identificationModule.nctId: "NCT02798406"
protocolSection.identificationModule.officialTitle: "A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA\u00ae) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.